Masimo (NASDAQ:MASI) Receives Hold Rating from Needham & Company LLC

Masimo (NASDAQ:MASI - Get Free Report)'s stock had its "hold" rating restated by Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports.

MASI has been the topic of several other research reports. Wells Fargo & Company lifted their target price on shares of Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Stifel Nicolaus reiterated a "buy" rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Piper Sandler lifted their target price on Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $179.67.

Masimo Stock Up 1.4 %

Shares of NASDAQ:MASI traded up $2.35 during mid-day trading on Thursday, hitting $172.29. 616,441 shares of the company traded hands, compared to its average volume of 542,867. The stock has a 50-day moving average price of $169.23 and a two-hundred day moving average price of $140.13. Masimo has a 12-month low of $101.61 and a 12-month high of $180.97. The stock has a market cap of $9.22 billion, a P/E ratio of 118.82 and a beta of 1.01. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.63 EPS. On average, equities research analysts forecast that Masimo will post 4.03 earnings per share for the current year.

Institutional Investors Weigh In On Masimo

Several large investors have recently added to or reduced their stakes in MASI. Edgestream Partners L.P. bought a new position in Masimo during the second quarter worth about $645,000. Simplify Asset Management Inc. lifted its stake in shares of Masimo by 120.4% during the 2nd quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider's stock valued at $2,729,000 after buying an additional 11,838 shares in the last quarter. ING Groep NV boosted its holdings in Masimo by 143.3% in the 3rd quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider's stock worth $32,119,000 after buying an additional 141,900 shares during the period. Westfield Capital Management Co. LP grew its stake in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after buying an additional 262,370 shares in the last quarter. Finally, National Bank of Canada FI raised its holdings in Masimo by 195.6% during the 3rd quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider's stock valued at $17,666,000 after acquiring an additional 87,675 shares during the period. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.